

Table 3. Clinical Laboratory Director Reporting Requirements

| | | | | | |
|---|---|--------------------|--|-------|--|
| ① | Arboviruses | ☎,* | <i>Haemophilus influenzae</i> , type b, isolated from a normally sterile site | ☑ | <i>Plasmodium</i> spp. |
| ☎,☎,* | <i>Bacillus anthracis</i> | ☑,* | <i>Haemophilus influenzae</i> , other, isolated from a normally sterile site | ☑ | Respiratory syncytial virus |
| ☎,* | <i>Bordetella pertussis</i> | ☑ | Hantavirus | ☎,+ | Rubella virus and anti-rubella-IgM serologies |
| ①,* | <i>Brucella</i> spp. | ☑ ¹ | Hepatitis A virus (anti-HAV-IgM serologies) | ①,* | <i>Salmonella</i> spp. |
| ①,* | <i>Burkholderia mallei</i> and <i>B. pseudomallei</i> | ☑ ¹ | Hepatitis B virus (anti-Hepatitis B core-IgM serologies, Hepatitis B surface or envelope antigen serologies, or detection of viral nucleic acid) | ☎ | SARS-associated corona virus |
| ☑ | <i>Campylobacter</i> spp. | ☑ ¹ | Hepatitis C virus | ①,* | <i>Shigella</i> spp. |
| ☑ | CD4-T-lymphocyte count of fewer than 200 per microliter of whole blood or CD4-T-lymphocyte percentage of total lymphocytes of less than 14% | ☑ ¹ | Hepatitis D virus | ☑ | <i>Streptococcus</i> Group A, isolated from a normally sterile site |
| ☑ | <i>Chlamydia trachomatis</i> | ☑ ¹ , + | Hepatitis E virus (anti-HEV-IgM serologies) | ☑ | <i>Streptococcus</i> Group B, isolated from a normally sterile site in an infant younger than 90 days of age |
| ☎,☎ | <i>Clostridium botulinum</i> toxin (botulism) | ☑ | HIV (by culture, antigen, antibodies to the virus, or detection of viral nucleic acid) | ☑,* | <i>Streptococcus pneumoniae</i> and its drug sensitivity pattern, isolated from a normally sterile site |
| ☑ | <i>Coccidioides</i> spp., by culture or serologies | ☑ | HIV—any test result for an infant (by culture, antigen, antibodies to the virus, or detection of viral nucleic acid) | ☑ | <i>Treponema pallidum</i> (syphilis) |
| ① | <i>Coxiella burnetti</i> | ☑ | Influenza virus | ☑ | <i>Trypanosoma cruzi</i> (Chagas disease) |
| ☑ | <i>Cryptosporidium</i> spp. | ☑,* | <i>Legionella</i> spp. (culture or DFA) | ①,* | Vancomycin-resistant or Vancomycin-intermediate <i>Staphylococcus aureus</i> |
| ① | <i>Cyclospora</i> spp. | ①,* | <i>Listeria</i> spp., isolated from a normally sterile site | ①,* | Vancomycin resistant <i>Staphylococcus epidermidis</i> |
| ☑ | Dengue virus | ☎,+ | Measles virus and anti-measles-IgM serologies | ☎,☎ | Variola virus (smallpox) |
| ☎,☎ | Emerging or exotic disease agent | ☑ ² | Methicillin-resistant <i>Staphylococcus aureus</i> , isolated from a normally sterile site | ①,* | <i>Vibrio</i> spp. |
| ☑ | <i>Entamoeba histolytica</i> | ①,+ | Mumps virus and anti-mumps-IgM serologies | ☎,☎ | Viral hemorrhagic fever agent |
| ① | <i>Escherichia coli</i> O157:H7 | ☑,* ³ | <i>Mycobacterium tuberculosis</i> complex and its drug sensitivity pattern | ☑ | West Nile virus |
| ①,* | <i>Escherichia coli</i> , Shiga-toxin producing | ☑ | <i>Neisseria gonorrhoeae</i> | ①,* | <i>Yersinia</i> spp. (other than <i>Y. pestis</i>) |
| ☎,☎,* | <i>Francisella tularensis</i> | ☎,* | <i>Neisseria meningitidis</i> , isolated from a normally sterile site | ☎,☎,* | <i>Yersinia pestis</i> (plague) |
| | | ☑ | Norovirus | | |
| <hr/> | | | | | |
| From December 1, 2008 until February 28, 2010 | | ☑ ⁴ | <i>Clostridium difficile</i> toxin | | |

Key:

- ☎ Submit a report immediately after receiving one specimen for detection of the agent. Report receipt of subsequent specimens within five working days after receipt.
- ☎ Submit a report within 24 hours after obtaining a positive test result.
- ① Submit a report within one working day after obtaining a positive test result.
- ☑ Submit a report within five working days after obtaining a positive test result or a test result specified in Table 3.
- * Submit an isolate of the organism for each positive culture to the Arizona State Laboratory at least once each week, as applicable.
- + For each positive test result, submit a specimen to the Arizona State Laboratory within 24 hours after obtaining the positive test result.
- ¹ When reporting a positive result for any of the specified tests, report the results of all other tests performed for the subject as part of the disease panel.
- ² Submit a report only when an initial positive result is obtained for an individual.
- ³ Submit an isolate of the organism only when an initial positive result is obtained for an individual, when a change in resistance pattern is detected, or when a positive result is obtained ≥ 12 months after the initial positive result is obtained for an individual.
- ⁴ For every eighth positive test result, submit a specimen to the Arizona State Laboratory or the Department's designee. A clinical laboratory director may aggregate specimens and submit specimens every five working days, rather than submitting individual specimens.